Lund-based MedVasc AB, a Swedish MedTech firm, introduced right now the profitable closing of a €917k financing spherical to help the ultimate product growth part for his or her catheter gadget and preparation for FDA regulatory approval in the USA.
The financing spherical attracted each present house owners and new buyers.
“We’re more than happy with the continued confidence from our buyers,” says Cathrin Johansson, CEO of MedVasc AB. “This funding offers us the chance to take decisive steps in the direction of reaching the US market, which is a vital milestone in our development journey.”
MedVasc AB was based in 2013 by Michael Åkesson and has over the last years, developed a remaining prototype, been granted patents and logos in all prioritised markets, and carried out a first-in-man medical examine.
Åkesson is a senior marketing consultant of interventional radiology and has an expertise of over twenty years with catheter primarily based remedies and prognosis. Beforehand he was the Head of the Division of Endovascular Surgical procedure on the Vascular Division, College Hospital SUS Malmö. He now works as a senior marketing consultant on the Scandinavian Venous Centre, Malmö.
He’s the primary proprietor of MedVASC AB and the inventor behind Solutio.
MedVasc has developed and patented the medical gadget Solutio, designed to enhance the anaesthetic process when treating varicose veins. For investigational use solely. The Solutio catheter has not been evaluated by the FDA and isn’t but out there on the market within the USA.
Solutio is designed to allow protected and exact native anesthesia throughout minimally invasive vascular procedures, e.g. varicose veins, (appropriate with thermal ablation remedy fibers), providing a brand new degree of management and affected person consolation for clinicians treating persistent venous issues.
The first focus of the funding will likely be to fund the manufacturing and testing of the ultimate design of Solutio, required for FDA clearance. Regulatory submission is deliberate for the primary half of 2026.
As well as, MedVasc will elevate a further spherical throughout 2025 for investments in medical and preclinical actions required for FDA clearance.
MedVasc can be taking part in SmiLe’s incubator programme – additionally primarily based in Lund. SmiLe is a number one enterprise hub that specialises in advancing life science and FoodTech startups from idea to commercialisation. So far, their flagship incubator programme has supported over 110 startups, facilitating their collective acquisition of greater than €1.05 billion in enterprise capital and contributing to 21 profitable IPOs.
